52.52

2.02% 1.04

After Hours: 52.41 -0.11 -0.21%

Cytokinetics Inc (CYTK)

Overview News Price History Option Chain Financials Why CYTK Down? Discussions Forecast Stock Split

Cytokinetics Inc stock is traded at $52.52, with a volume of 1.13M. It is up +2.02% in the last 24 hours and down -7.34% over the past month. Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Previous Close:

$51.48

Open:

$51.31

24h Volume:

1.13M

Relative Volume:

1.00

Market Cap:

$6.18B

Revenue:

$3.13M

Net Income/Loss:

$-545.28M

P/E Ratio:

-9.5145

EPS:

-5.52

Net Cash Flow:

$-401.27M

1W Performance:

+1.96%

1M Performance:

-7.34%

6M Performance:

-19.53%

1Y Performance:

+44.60%

1-Day Range:

$50.88

$53.00

1-Week Range:

$50.53

$53.00

52-Week Range:

$30.68

$110.25

Cytokinetics Inc Stock (CYTK) Company Profile

Name

Cytokinetics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

(650) 624-3000

Address

350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

Employee

564

Twitter

@Cytokinetics

Next Earnings Date

2024-11-06

Latest SEC Filings

CYTK's Discussions on Twitter

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-24-24	Downgrade	UBS	Buy → Neutral
Jan-05-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-23	Initiated	Goldman	Buy
Nov-07-23	Initiated	B. Riley Securities	Buy
Aug-15-23	Initiated	SVB Securities	Outperform
Feb-17-23	Initiated	BofA Securities	Neutral
Dec-23-22	Reiterated	Needham	Buy
Dec-20-22	Initiated	Truist	Buy
Oct-11-22	Initiated	UBS	Buy
Jan-28-22	Initiated	Goldman	Buy
Dec-22-21	Initiated	Oppenheimer	Outperform
Dec-10-21	Initiated	JP Morgan	Overweight
Oct-07-21	Initiated	Jefferies	Buy
Mar-12-21	Initiated	Wolfe Research	Outperform
Feb-18-21	Initiated	Barclays	Overweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-29-20	Initiated	Goldman	Neutral
Jul-10-20	Initiated	Raymond James	Strong Buy
May-05-20	Initiated	Mizuho	Buy
Apr-09-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-10-18	Resumed	Morgan Stanley	Equal-Weight
Nov-22-17	Reiterated	Morgan Stanley	Overweight
Nov-22-17	Downgrade	Needham	Strong Buy → Buy
Nov-21-17	Reiterated	H.C. Wainwright	Buy
Jul-31-17	Initiated	Morgan Stanley	Overweight
Mar-08-17	Initiated	Rodman & Renshaw	Buy
Feb-06-17	Upgrade	Needham	Buy → Strong Buy
Dec-16-16	Initiated	Cantor Fitzgerald	Overweight
Jul-28-16	Reiterated	Needham	Buy
Nov-10-15	Reiterated	FBR Capital	Outperform
Nov-09-15	Reiterated	ROTH Capital	Buy
Jul-24-15	Reiterated	MLV & Co	Buy
Dec-31-14	Reiterated	ROTH Capital	Buy
Nov-04-14	Upgrade	MLV & Co	Hold → Buy
Apr-28-14	Reiterated	Needham	Buy

View All

Cytokinetics Inc Stock (CYTK) Latest News

04:25 AM

Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024 - The Manila Times

04:25 AM

04:02 AM

Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific ... - NRToday.com

04:02 AM

07:46 AM

Earnings To Watch: Cytokinetics Inc (CYTK) Reports Q3 2024 Resul - GuruFocus.com

07:46 AM

05:08 AM

Cytokinetics, Incorporated (NASDAQ:CYTK) Position Increased by Harbor Capital Advisors Inc. - MarketBeat

05:08 AM

01:54 AM

Vanguard Group Inc's Strategic Acquisition of Cytokinetics Inc S - GuruFocus.com

01:54 AM

Nov 04, 2024

Robert I. Blum Sells 5,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - MarketBeat

Nov 04, 2024

Cytokinetics CEO Robert Blum sells $258,150 in stock - Investing.com

Nov 04, 2024

Cytokinetics CEO Robert Blum sells $258,150 in stock By Investing.com - Investing.com UK

Nov 04, 2024

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM

Nov 04, 2024

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 04, 2024

Nov 01, 2024

Insider Sale at Cytokinetics Inc (CYTK): EVP Research & Developm - GuruFocus.com

Nov 01, 2024

abrdn plc Trims Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat

Nov 01, 2024

Oct 31, 2024

Cytokinetics EVP Malik Fady Ibraham sells $378,930 in stock By Investing.com - Investing.com Australia

Oct 31, 2024

Cytokinetics director Wendall Wierenga sells shares worth $232,617 - Investing.com India

Oct 31, 2024

Cytokinetics EVP Malik Fady Ibraham sells $378,930 in stock - Investing.com

Oct 31, 2024

Cytokinetics director Wendall Wierenga sells shares worth $232,617 By Investing.com - Investing.com UK

Oct 31, 2024

Oct 30, 2024

Cytokinetics, Incorporated Announces Presentations At the 23 Annual HFSA Scientific Meeting - Marketscreener.com

Oct 30, 2024

Oct 29, 2024

HEART FAILURE (HF) WITH REDUCED EJECTION FRACTION (HFREF) - openPR

Oct 29, 2024

Oct 24, 2024

Moody Aldrich Partners LLC Sells 23,174 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat

Oct 24, 2024

Cytokinetics' SWOT analysis: aficamten's promise drives stock outlook - Investing.com

Oct 24, 2024

Oct 23, 2024

Cytokinetics to Announce Third Quarter Results on November 6, 2024 - StockTitan

Oct 23, 2024

Oct 22, 2024

Possible Bearish Signals With Cytokinetics Insiders Disposing Stock - Simply Wall St

Oct 22, 2024

Oct 19, 2024

Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Oct 19, 2024

Oct 18, 2024

Cytokinetics (NASDAQ:CYTK) Stock Rating Reaffirmed by Cantor Fitzgerald - MarketBeat

Oct 18, 2024

Cytokinetics stock sees no change as Mizuho reiterates Outperform rating after aficamten update - Investing.com Canada

Oct 18, 2024

Oct 17, 2024

Cytokinetics EVP sells $395,554 in stock By Investing.com - Investing.com South Africa

Oct 17, 2024

Cytokinetics retains buy rating, stock target with positive outlook By Investing.com - Investing.com Canada

Oct 17, 2024

Cytokinetics (NASDAQ:CYTK) Given Buy Rating at Needham & Company LLC - MarketBeat

Oct 17, 2024

Oct 16, 2024

Cytokinetics EVP sells $395,554 in stock - Investing.com

Oct 16, 2024

Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 7,300 Shares of Stock - MarketBeat

Oct 16, 2024

Is Cytokinetics Inc. (CYTK) the Most Promising Biotech Stock According to Hedge Funds? - Insider Monkey

Oct 16, 2024

Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day - The Manila Times

Oct 16, 2024

Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Bought by Cetera Investment Advisers - MarketBeat

Oct 16, 2024

Oct 14, 2024

From amoeboid myosin to unique targeted medicines for a genetic cardiac disease - Frontiers

Oct 14, 2024

Oct 11, 2024

Cytokinetics CEO sells $278k in company stock - Investing.com India

Oct 11, 2024

Oct 10, 2024

Cytokinetics CEO sells $278k in company stock By Investing.com - Investing.com Australia

Oct 10, 2024

Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Sells 5,000 Shares of Stock - MarketBeat

Oct 10, 2024

SG Americas Securities LLC Cuts Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat

Oct 10, 2024

Oct 09, 2024